Wargo Jennifer A, Reddy Sangeetha M, Reuben Alexandre, Sharma Padmanee
Department of Surgical Oncology, Genomic Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA.
Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 1400 Holcombe Blvd, Unit 463, Houston, TX 77030, USA.
Curr Opin Immunol. 2016 Aug;41:23-31. doi: 10.1016/j.coi.2016.05.006. Epub 2016 May 27.
Immune monitoring in the tumor microenvironment allows for important insights into immune mechanisms of response and resistance to various cancer treatments; however clinical challenges exist using current strategies. Significant questions remain regarding monitoring of archival versus fresh tissue, assessment of static versus dynamic markers, evaluation of limited tissue samples, and the translation of insights gained from immunologically 'hot' tumors such as melanoma to other 'cold' tumor microenvironments prevalent in other cancer types. Current and emerging immune monitoring strategies will be examined herein, and genomic-based assays complementing these techniques will also be discussed. Finally, host genomic and external environmental factors influencing anti-tumor immune responses will be considered, including the role of the gut microbiome. Though optimal immune monitoring techniques are in evolution, great promise exists in recent advances that will help guide patient selection as far as type, sequence, and combination of therapeutic regimens to enhance anti-tumor immunity and clinical responses.
肿瘤微环境中的免疫监测有助于深入了解对各种癌症治疗的反应和耐药性的免疫机制;然而,使用当前策略存在临床挑战。关于存档组织与新鲜组织的监测、静态标记物与动态标记物的评估、有限组织样本的评估,以及从免疫“热”肿瘤(如黑色素瘤)获得的见解向其他癌症类型中普遍存在的其他“冷”肿瘤微环境的转化,仍存在重大问题。本文将研究当前和新兴的免疫监测策略,还将讨论补充这些技术的基于基因组的检测方法。最后,将考虑影响抗肿瘤免疫反应的宿主基因组和外部环境因素,包括肠道微生物群的作用。尽管最佳免疫监测技术仍在不断发展,但最近的进展大有可为,将有助于指导患者在治疗方案的类型、顺序和组合方面的选择,以增强抗肿瘤免疫力和临床反应。